Barbara Skopec1, Matevz Skerget2, Darja Zontar2, Vesna Zadnik3, Samo Zver2. 1. Department of Hematology, University Medical Center Ljubljana, Zaloska cesta 7, 1000, Ljubljana, Slovenia. barbara.skopec@kclj.si. 2. Department of Hematology, University Medical Center Ljubljana, Zaloska cesta 7, 1000, Ljubljana, Slovenia. 3. Institute of Oncology, Ljubljana, Slovenia.
Abstract
BACKGROUND:Autologous hematopoietic stem cell transplantation (aHSCT) is the recommended standard upfront treatment for transplant eligible myeloma patients. Considering possible complications related to chemotherapy-cytokine mobilization, cytokine-alone mobilization is often used. We compared mobilization with filgrastim alone to pegfilgrastim alone in newly diagnosed myeloma patients after induction treatment withbortezomib and dexamethasone. The comparison was made between peripheral blood stem cell (PBSC) yields, number of apheresis, hematopoietic stem cell subsets, and time to neutrophil and platelet engraftment after aHSCT. METHODS:A total of 42 myeloma patients were prospectively enrolled in the study: 21 received filgrastim, 21 pegfilgrastim. Flow cytometry was used to determine the number of PBSC, myeloid, lymphoid, and megakaryocyte precursors in peripheral blood and apheresis product on day 1 of apheresis. RESULTS: The median number of collected PBSC was 5.05 × 106/kg in the filgrastim and 4.66 × 106/kg in the pegfilgrastim group (p = 0.428). The median number of apheresis was 2.5 in the filgrastim and 2 in the pegfilgrastim group (p = 0.901). The number of megakaryocyte precursors in peripheral blood was significantly higher in the filgrastim group, but not in the apheresis products. There were no statistically significant differences in the myeloid and lymphoid precursors in the peripheral blood and in the apheresis products. The median time to neutrophil and platelet engraftment was 13 days and 16.5 days for filgrastim and 13 days and 16 days for pegfilgrastim group. CONCLUSIONS: We can conclude that pegfilgrastim alone is at least equally successful as filgrastim alone for the PBSC mobilization in newly diagnosed myeloma patients.
RCT Entities:
BACKGROUND: Autologous hematopoietic stem cell transplantation (aHSCT) is the recommended standard upfront treatment for transplant eligible myelomapatients. Considering possible complications related to chemotherapy-cytokine mobilization, cytokine-alone mobilization is often used. We compared mobilization with filgrastim alone to pegfilgrastim alone in newly diagnosed myelomapatients after induction treatment with bortezomib and dexamethasone. The comparison was made between peripheral blood stem cell (PBSC) yields, number of apheresis, hematopoietic stem cell subsets, and time to neutrophil and platelet engraftment after aHSCT. METHODS: A total of 42 myelomapatients were prospectively enrolled in the study: 21 received filgrastim, 21 pegfilgrastim. Flow cytometry was used to determine the number of PBSC, myeloid, lymphoid, and megakaryocyte precursors in peripheral blood and apheresis product on day 1 of apheresis. RESULTS: The median number of collected PBSC was 5.05 × 106/kg in the filgrastim and 4.66 × 106/kg in the pegfilgrastim group (p = 0.428). The median number of apheresis was 2.5 in the filgrastim and 2 in the pegfilgrastim group (p = 0.901). The number of megakaryocyte precursors in peripheral blood was significantly higher in the filgrastim group, but not in the apheresis products. There were no statistically significant differences in the myeloid and lymphoid precursors in the peripheral blood and in the apheresis products. The median time to neutrophil and platelet engraftment was 13 days and 16.5 days for filgrastim and 13 days and 16 days for pegfilgrastim group. CONCLUSIONS: We can conclude that pegfilgrastim alone is at least equally successful as filgrastim alone for the PBSC mobilization in newly diagnosed myelomapatients.
Authors: A M Kamel; N El-Sharkawy; H K Mahmoud; M-R Khalaf; A El Haddad; O Fahmy; R Abd El Fattah; D Sayed Journal: Bone Marrow Transplant Date: 2005-01 Impact factor: 5.483
Authors: G A Donzella; D Schols; S W Lin; J A Esté; K A Nagashima; P J Maddon; G P Allaway; T P Sakmar; G Henson; E De Clercq; J P Moore Journal: Nat Med Date: 1998-01 Impact factor: 53.440
Authors: Ville Varmavuo; Pentti Mäntymaa; Raija Silvennoinen; Tapio Nousiainen; Taru Kuittinen; Esa Jantunen Journal: Transfusion Date: 2012-08-15 Impact factor: 3.157
Authors: S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel Journal: Blood Date: 2011-02-03 Impact factor: 22.113
Authors: L B To; M M Roberts; D N Haylock; P G Dyson; A L Branford; D Thorp; J Q Ho; G W Dart; N Horvath; M L Davy Journal: Bone Marrow Transplant Date: 1992-04 Impact factor: 5.483
Authors: K E Herbert; P Gambell; E K Link; A Mouminoglu; D M Wall; S J Harrison; D S Ritchie; J F Seymour; H M Prince Journal: Bone Marrow Transplant Date: 2012-07-30 Impact factor: 5.483